 AIM ImmunoTech Inc NYSE:AIM has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program EAP evaluating its investigational drug Ampligen as a therapeutic for Long COVID. The immuno-pharma firm said the preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen and, based on these early results, the company is working to move forward with a Phase 2 controlled trial. 